232 related articles for article (PubMed ID: 31703648)
1. Influence of pre-operative oral carbohydrate loading vs. standard fasting on tumor proliferation and clinical outcome in breast cancer patients ─ a randomized trial.
Lende TH; Austdal M; Varhaugvik AE; Skaland I; Gudlaugsson E; Kvaløy JT; Akslen LA; Søiland H; Janssen EAM; Baak JPA
BMC Cancer; 2019 Nov; 19(1):1076. PubMed ID: 31703648
[TBL] [Abstract][Full Text] [Related]
2. Metabolic consequences of perioperative oral carbohydrates in breast cancer patients - an explorative study.
Lende TH; Austdal M; Bathen TF; Varhaugvik AE; Skaland I; Gudlaugsson E; Egeland NG; Lunde S; Akslen LA; Jonsdottir K; Janssen EAM; Søiland H; Baak JPA
BMC Cancer; 2019 Dec; 19(1):1183. PubMed ID: 31801490
[TBL] [Abstract][Full Text] [Related]
3. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Van Asten K; Slembrouck L; Olbrecht S; Jongen L; Brouckaert O; Wildiers H; Floris G; Van Limbergen E; Weltens C; Smeets A; Paridaens R; Giobbie-Hurder A; Regan MM; Viale G; Thürlimann B; Vergote I; Christodoulou E; Van Calster B; Neven P
Oncologist; 2019 Feb; 24(2):165-171. PubMed ID: 30171067
[TBL] [Abstract][Full Text] [Related]
5. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
6. Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study.
Wei JL; Zhang JX; Fu DY
World J Surg Oncol; 2018 Dec; 16(1):236. PubMed ID: 30558615
[TBL] [Abstract][Full Text] [Related]
7. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
8. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
9. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer.
Mulligan AM; O'Malley FP; Ennis M; Fantus IG; Goodwin PJ
Breast Cancer Res Treat; 2007 Nov; 106(1):39-47. PubMed ID: 17221153
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
11. Prognostic effect of preoperative serum estradiol level in postmenopausal breast cancer.
Kim JY; Han W; Moon HG; Ahn SK; Kim J; Lee JW; Kim MK; Kim T; Noh DY
BMC Cancer; 2013 Oct; 13():503. PubMed ID: 24160328
[TBL] [Abstract][Full Text] [Related]
12. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?
Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K
Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210
[TBL] [Abstract][Full Text] [Related]
13. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
14. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
15. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
16. Glycemic load, glycemic index and breast cancer risk in a prospective cohort of Swedish women.
Larsson SC; Bergkvist L; Wolk A
Int J Cancer; 2009 Jul; 125(1):153-7. PubMed ID: 19319984
[TBL] [Abstract][Full Text] [Related]
17. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Krop IE; Mayer IA; Ganju V; Dickler M; Johnston S; Morales S; Yardley DA; Melichar B; Forero-Torres A; Lee SC; de Boer R; Petrakova K; Vallentin S; Perez EA; Piccart M; Ellis M; Winer E; Gendreau S; Derynck M; Lackner M; Levy G; Qiu J; He J; Schmid P
Lancet Oncol; 2016 Jun; 17(6):811-821. PubMed ID: 27155741
[TBL] [Abstract][Full Text] [Related]
18. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
19. DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
Ansems M; Hontelez S; Looman MW; Karthaus N; Bult P; Bonenkamp JJ; Jansen JH; Sweep FC; Span PN; Adema GJ
J Natl Cancer Inst; 2010 Jan; 102(1):54-68. PubMed ID: 20008677
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
Keshgegian AA; Cnaan A
Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
